Drug Screening Market Size To Reach $11.99 Billion By 2030

Drug Screening Market Growth & Trends

The global drug screening market size is anticipated to reach USD 11.99 billion by 2030 and is growing at a CAGR of 4.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by increasing workplace safety concerns, regulatory compliance, and requirement for accurate detection of substance abuse, aided by technological advancements in testing methods.

The increase in number of adults in contact with drug and alcohol services in England has increased from 275,896 in 2020 - 2021­ to 289,215 in 2021 - 2022, representing a 4.8% rise, which signifies a growing prevalence of substance abuse in the country. The rising prevalence of substance abuse further propels the need for effective prevention and treatment strategies, including the expansion of access to evidence-based treatment options and public health campaigns to raise awareness about the risks of drug and alcohol misuse.

Similarly, the incidence of illegal substance use among Americans aged 12 and older in 2020 was around 37.31 million, and shows a 3.8% year-over-year increase over the years; this rising prevalence serves as a significant driver for the market. This increase highlights the urgent need for comprehensive drug screening programs in workplaces, schools, and healthcare settings to ensure safety, compliance with regulations, and provision of appropriate care and support for individuals struggling with substance abuse.

Furthermore, initiatives by market players such as new product launches, mergers, acquisitions, and others contribute to market growth. For instance, in February 2024, Mobile Health, the leading drug testing provider in NYC, introduced rapid drug testing for employers, ensuring results in an hour or less. With a focus on urine-based testing for accuracy and versatility, this innovation advances the hiring process, revolutionizing talent acquisition in NYC. In addition, in December 2023, the FDA's approval of the AvertD test, which assesses an individual's risk of developing opioid use disorder through genetic markers, marks a significant innovation in the fight against the opioid crisis. This test, developed by AutoGenomics, Inc., is designed to be used before a patient is first exposed to oral opioid pain medications, particularly in patients scheduled for surgical procedures. The test is intended to help patients and healthcare providers make informed decisions about opioid use, potentially reducing the risk of addiction and misuse.

The approval of AvertD is part of FDA's broader efforts to address opioid crisis, which includes the introduction of FDA Overdose Prevention Framework in August 2022 and the approval of nonprescription naloxone nasal spray products in March and July 2023. The FDA's commitment to addressing these crisis is evident in its continued support for the development of medical devices that can help assess and mitigate the risk of opioid use disorder.

 Request a free sample copy or view report summary: Drug Screening Market Report

Drug Screening Market Report Highlights

• Consumables dominated the product type segment with the fastest revenue market share in 2023 and is anticipated to grow at fastest growth rate over the forecast period owing to extensive R&D initiatives undertaken by major players to develop kits

• Based on type segment, urine sample dominated the market with the largest revenue share in 2023 attributed to the ease of collection. Urine drug testing is generally more cost-effective compared to other testing methods, such as hair testing

• Drug treatment centers end-use segment dominated the market in 2023, attributed to the increasing focus on substance abuse treatment and rehabilitation, leading to a higher demand for drug testing services in these centers

• North America dominated the global market owing to factors such as advanced healthcare infrastructure, the region’s high consumption of illegal substances, and the necessity for workplace drug tests 

Drug Screening Market Segmentation

Grand View Research has segmented the global drug screening market based on product type, sample type, end-use, and region:

Drug Screening Product Type Category Outlook (Revenue, USD Million, 2018 - 2030­)

• Instruments

  • Immunoassays Analyzers

  • Chromatography Instruments

  • Breath Analyzer

    • Fuel Cell Breath Analyzer

    • Semi-Conductor Breath Analyzer

    • Others Breath Analyzer

• Rapid Testing Devices

  • Urine Testing Devices

    • Drug Testing Cups

    • Dip Cards

    • Drug Testing Cassettes

  • Oral Fluid Testing Devices

• Consumables

  • Assay Kits

  • Sample Collection Devices

  • Calibrators & Controls

  • Other Consumables

• Services and Others

 Drug Screening Sample Type Outlook (Revenue, USD Million, 2018 - 2030)

• Urine Samples

• Breath Samples

• Oral Fluid Samples

• Hair Samples

• Other Samples

Drug Screening End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Criminal Justice & Law Enforcement Agencies

• Workplaces

• Drug Treatment Centers

• Individual Users

• Pain Management Centers

• Schools & Colleges

• Others

Drug Screening Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait 

List of Key Players in the Drug Screening Market

• Abbott

• Quest Diagnostics Incorporated

• F. Hoffmann-La Roche Ltd

• Thermo Fisher Scientific Inc.

• Siemens Healthcare AG

• Laboratory Corporation of America Holdings

• Alfa Scientific Designs, Inc.

• OraSure Technologies, Inc.

• Omega Laboratories, Inc.

• Drägerwerk AG & Co. KGaA

• Bio-Rad Laboratories, Inc.